Navigating the Forces Shaping Oncology

  • New Century Health and Humana Surpass Monumental 10 Years of Partnership in High-Value Oncology Care

    New Century Health and Humana Surpass Monumental 10 Years of Partnership in High-Value Oncology Care

    New Century Health and Humana's national partnership improves patient experience and eases administrative burdens on provider practices.

    Read Press Release
  • Leading Causes: Interrogating the “Why” Behind Health Inequity in Cancer Care

    Leading Causes: Interrogating the “Why” Behind Health Inequity in Cancer Care

    How do social determinants of health impact outcomes in cancer care? New Century Health Associate CMO Dr. Monica Soni and Radiation Oncologist Dr. Onyinye Balogun discuss.

    Watch Video
  • ×

    First Name
    Last Name
    Company Name
    Thank you!
    Error - something went wrong!
  • Bridging the Gaps in Advance Care Planning in Oncology

    Bridging the Gaps in Advance Care Planning in Oncology

    New Century Health and our Vital Decisions solution seek to ensure more cancer patients receive end-of-life care that aligns with their wishes.

    Watch Video
  • New Century Health Partner Cancer Care Specialists of Illinois Earns $3.6 Million from Medicare through Federal Oncology Care Model

    New Century Health Partner Cancer Care Specialists of Illinois Earns $3.6 Million from Medicare through Federal Oncology Care Model

    NCH’s high-value clinical oncology pathways, patient triage programs and provider engagement strategies help community practice to succeed in value-based payment program.

    Read Press Release
  • Let's Go
  • Still Bracing for the Surge in Advanced Cancer Cases

    Still Bracing for the Surge in Advanced Cancer Cases

    The predicted wave of late-stage cancers is taking longer to materialize than we expected.

    Watch Video
  • The Pandemic's Disproportionate Impact on Health Care Disparities and Cancer

    The Pandemic's Disproportionate Impact on Health Care Disparities and Cancer

    Our associate chief medical officer shares her insights with the American Journal of Managed Care's podcast.

    Listen to Podcast
  • Cancer Moonshot 2.0: Three Big Questions to Track

    Cancer Moonshot 2.0: Three Big Questions to Track

    Which components of the recently announced Cancer Moonshot should get high priority for the initiative to succeed? Our chief medical officer, Dr. Andrew Hertler, outlines three key questions to track.

    Watch Video
  • Developing a playbook to tackle health inequities in cancer care

    Developing a playbook to tackle health inequities in cancer care

    New Century Health Associate Chief Medical Officer Monica Soni explores health inequities in cancer cares and shares strategies for how to address them.

    Watch Video
  • Accelerated Drug Approvals Present a Mounting Challenge to Oncologists

    Accelerated Drug Approvals Present a Mounting Challenge to Oncologists

    Dr. Andrew Hertler explains three key criteria for evaluating fast-tracked drugs.

    Read External Article
  • Patient Impact Story: Clinical Review Catches Potential Medical Error

    Patient Impact Story: Clinical Review Catches Potential Medical Error

    Red flags cause clinical reviewers to question a radiation oncologist’s diagnosis.

    Watch Video
  • Panel Discussion: Oncology Care Reimagined

    Panel Discussion: Oncology Care Reimagined

    Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.

    Watch Video
  • Location, Location, Location. That Also Applies to Cancer Treatment.

    Location, Location, Location. That Also Applies to Cancer Treatment.

    Home-based chemotherapy infusions may offer convenience but also raise a host of questions.

    Read External Article
  • Shouldering the Burden and Financial Toxicity of Part D Cancer Drugs

    Shouldering the Burden and Financial Toxicity of Part D Cancer Drugs

    Discussing drug costs should be a core tenet of shared decision-making.

    Watch Video
  • Specialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler Says

    Specialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler Says

    Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.

    Read External Article
  • Learn More
  • The Mainstreaming of Targeted Lung Cancer Treatment

    The Mainstreaming of Targeted Lung Cancer Treatment

    Our CMO speaks with Managed Care Executive about the promise and perils of genomic testing.

    Read External Article
  • Health Systems' Rare Rejection of Alzheimer's Drug Sparks Questions About FDA Approvals

    Health Systems' Rare Rejection of Alzheimer's Drug Sparks Questions About FDA Approvals

    Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.

    Watch Video
  • Specialty Pharmacies Grapple with Assessing Costs and Value of Oncology Therapies

    Specialty Pharmacies Grapple with Assessing Costs and Value of Oncology Therapies

    Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.

    Watch Video
  • Hitting the Brakes on Fast-Tracked Drugs

    Hitting the Brakes on Fast-Tracked Drugs

    The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.

    Watch Video
  • New Century Health Supports Neighborhood Health Plan of Rhode Island with Comprehensive Oncology Management Services

    New Century Health Supports Neighborhood Health Plan of Rhode Island with Comprehensive Oncology Management Services

    New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncology specialty management services to Neighborhood Health Plan of Rhode Island.

    Watch Video
  • CMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting

    CMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting

    New Century Health CMO, Dr. Andrew Hertler, shares his thoughts on the recent FDA meetings to review the merits of approved cancer drugs.

    Watch Video
  • loading
    Loading More...